ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1015

ALPREG: A Multicenter Study of Maternal and Neonatal Outcomes Among Pregnant Women with Alport Syndrome in the United States

Session Information

Category: Women's Health and Kidney Diseases

  • 2200 Women's Health and Kidney Diseases

Authors

  • Allam, Krishna C, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Alam, Sreyoshi Fatima, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Kattah, Andrea G., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Brophy, Kelcie, University of Michigan, Ann Arbor, Michigan, United States
  • Oliverio, Andrea L., University of Michigan, Ann Arbor, Michigan, United States
  • Rheault, Michelle N., University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Nachman, Patrick H., University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Koubar, Sahar, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
Background

A patient-reported survey of women with Alport syndrome (AS) in the United States revealed a high burden of adverse pregnancy outcomes, including preeclampsia and preterm birth. To further investigate maternal and fetal outcomes in AS, we launched a national multicenter study.

Methods

We conducted a retrospective chart review of women ≥18 years with confirmed AS to evaluate their maternal and neonatal outcomes. Participants were enrolled from three U.S. centers between January 2015 and December 2024, with data analyzed descriptively at the pregnancy level at this stage of the study.

Results

We identified 32 women with Alport syndrome who experienced 56 pregnancies beyond 20 weeks gestation. 83.9% were White and their mean age at delivery was 29.6% ± 6.4 years. Assisted reproduction techniques were used in 16.1% of cases. Of the 33 pregnancies with available genetic testing, 36.3% had X-linked, 48.5% autosomal dominant, and 6.1% autosomal recessive AS. Chronic hypertension was noted in 17.9% of pregnancies. Key maternal complications included cesarean delivery (21.6%), gestational hypertension (12.5%), and preeclampsia (14.3%). Neonatal outcomes included preterm birth before 37 weeks in 17.9%, with 5.4% before 34 weeks. The mean birth weight was 3288 ± 595 grams, and 6.4% of neonates required NICU admission.

Conclusion

These preliminary findings are based on data from 3 of the 10 participating centers in the ALPREG study across the U.S. The results will be compared to a propensity-matched cohort of pregnant women with similar stages of CKD but different underlying causes, to better isolate and understand the specific risks associated with Alport syndrome.

Digital Object Identifier (DOI)